regulatory
confidence high
sentiment positive
materiality 0.50
Revolution Medicines receives FDA national priority voucher for daraxonrasib
Revolution Medicines, Inc.
- FDA granted a non-transferrable voucher under the Commissioner's National Priority Voucher pilot program.
- Voucher is for daraxonrasib, the company's RAS(ON) multi-selective inhibitor.
- Announcement made on October 16, 2025; no financial terms disclosed.